APSR2026-537

 
Late-Breaking
Submitted
Poster Presentation
 
AP08-049
P104
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1215646-46904-HDR APSR.pptx_433507.pdf
Format: PDF Only
06. Tuberculosis
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Farina Kamal Hizat * Hospital Tawau Internal Medicine Tawau Malaysia
Muhammad Khairul Taufiq Rosli - Hospital Tawau Respiratory Tawau Malaysia
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Farina
Kamal Hizat
fnakamal03@gmail.com
+60182040215
31-40
Malaysia
Case Report
Clinical utility and safety of optimized-dose rifampicin (20 mg/kg) in complex tuberculosis: a case series
Maximum 25 words
Abstract Content
 
 
 
 
Standard 10 mg/kg rifampicin (RIF) dosing often results in suboptimal serum concentrations, particularly in patients with metabolic or hepatic comorbidities. While 20 mg/kg (R20) regimens show promise for treatment shortening, clinical data regarding its use in high-risk scenarios such as baseline hepatic impairment, uncontrolled diabetes mellitus (DM), and neuro-tuberculosis—remain sparse in real-world settings. We report the outcomes of four patients managed with an optimized R20 strategy.
Four patients were initiated on an R20-based intensive phase regimen: Case 1 (Hepatic Safety): A patient with baseline transaminitis (AST 66 U/L, ALT 48 U/L) demonstrated biochemical stability throughout the 8-week induction phase (final AST 68 U/L, ALT 50 U/L), with no evidence of drug-induced liver injury. Cases 2 & 3 (Metabolic Challenges): Two patients with significant hyperglycaemia (HbA1c 11.8% and 8.0%) and high bacillary loads (Smear 3+) achieved rapid sputum conversion to negative within 60 days of R20 therapy. Case 4 (CNS IRIS): A patient with brain tuberculoma on R20 developed a focal paradoxical reaction (immune reconstitution inflammatory syndrome) shortly after dexamethasone cessation. Despite the inflammatory surge, the patient showed radiological improvement, indicating potent RIF CNS-penetration.
These cases highlight R20 as a robust dosing strategy in complex TB. In DM, where standard RIF dosing is frequently associated with suboptimal Cmax (peak plasma concentration), R20 appears to facilitate faster bacillary clearance. The occurrence of IRIS in Case 4 further underscores the enhanced pharmacokinetics of higher-dose RIF across the blood-brain barrier. Furthermore, the stable hepatic profile in Case 1 suggests that 20 mg/kg is well-tolerated even in borderline candidates. While effective, clinicians must remain vigilant for potent immunological responses in CNS-involved disease, necessitating individualized steroid tapers.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Rifampicin, Diabetes Mellitus, Tuberculoma
maximum 3 keywords and no abbreviations, separated by commas
The authors declare that they have no conflicts of interest. This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
280